ChinaPeptides

ChinaPeptides Co., Ltd. (QYAOBIO) (trading as QYB; qyaobiopeptides.com) is a peptide supplier trading as QYB from Shanghai, China, incorporated in 2008, whose catalogue centres on custom synthesis alongside a range of stock research peptides.^[1][2]

The organisation is one of twenty-eight covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in 2008, the organisation has a mid-length operating history among the entities covered here.^[1] It trades under two names — a company name and the designation QYAOBIO — which appear together in its own material and separately in purchaser reports. Both are recorded in the article's opening sentence and in the infobox so that a reader arriving under either reaches the same page.^[2]

The distinguishing feature of the catalogue is its emphasis on custom synthesis: sequences made to a purchaser's specification rather than drawn from stock. That is a materially different business from stock distribution, and this article treats it as such.

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Purchaser reports on custom orders describe a quotation stage, a stated lead time, and delivery with a certificate that in this set has usually included a mass-confirmation result alongside the purity figure.^[5] Mass confirmation by mass spectrometry addresses a question that a purity figure does not — whether the material is the intended sequence at all — and its presence on a custom-synthesis certificate is the minimum a purchaser should expect.^[6]

Stock-item reports describe conventional practice with purity-and-appearance certificates. As elsewhere, self-published claims about facilities are not corroborated here.^[2]

A custom-synthesis house and a stock distributor differ in the risks a purchaser carries. Custom work introduces the possibility of a synthesis that is technically successful but not the sequence intended; stock distribution introduces the possibility of a mislabelled vial. Neither risk is hypothetical and the mitigations differ.^[6]

Submitted reports on QYB material to July 2026 divide roughly evenly between stock and custom items. For custom items, several purchasers ran independent mass confirmation and reported agreement with the supplier's own figure.^[5]

That is a stronger form of verification than a purity comparison, because it addresses identity rather than relative composition. It remains a statement about individual samples: none was drawn under a documented chain of custody, and identity confirmation on one vial says nothing about the next.^[5][7]

Catalogue lines dispatch from held stock. Custom synthesis is the part of the operation submissions describe most often: quoted individually with a timeline, and delivered against it.^[5][2]

Minimum order quantity is one vial for catalogue lines. Custom work carries a synthesis-scale minimum, quoted with the timeline.

The certificate names the lot and the release date and reports purity and appearance. For custom work it carries mass-spectrometric identity confirmation alongside the chromatographic purity, which matters more on a custom order than on a stock one: a technically clean synthesis of the wrong sequence is invisible to a purity figure and visible to a mass.^[6]

To obtain the batch record, quote the lot identifier — or, for custom work, the quotation reference — and request the mass spectrum, the analytical conditions and the water determination.

The one check that needs no equipment is to read the lot identifier printed on the vial and confirm that the same string appears on the certificate and on the invoice. Where the three agree, the document describes the object; where they do not, nothing else in the documentation can be relied on until the discrepancy is resolved. See Lot traceability. This paragraph is standing text on all twenty-eight organisation articles, per the discussion linked from the talk page.

Material described here is labelled for research use only and is not approved for human use in any jurisdiction. PeptidePedia sells nothing, takes no commission, and records this section because a reader who cannot tell which documents to ask for cannot check anything a supplier tells them.

Go to the QYB catalogue →

The PeptidePedia tally records 902 self-reported submissions to July 2026. Recurring themes are the execution of custom-synthesis work and the presence of mass-confirmation documentation alongside the chromatographic figure, which is the pairing a custom order most needs and least often gets.^[4] Self-selected; reception rather than quality.^[4]

The reception figure above is a count of self-reported submissions to PeptidePedia, not a score: this wiki publishes none, and the figure says how many people wrote in rather than how good anything is. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

• Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
• It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
• It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.^[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.^[4]

Submissions are reproduced as written, with the submitter's own wording. They are self-reported and unverified, and are quoted to show what the tally is made of rather than to support any claim about the organisation.

8 vials from a melanotan II 10 mg consignment were weighed against the stated fill; all fell within two per cent. The stability-indicating character of the method is stated rather than assumed.

The paperwork included a residual-solvent screen that had not been requested. Peptide content was reported at 97.9%. Further submissions covering later lots would be useful.

The release carries a name and a date rather than an initial. No relationship exists between this contributor and the supplier beyond the transaction described.

The batch record arrived attached to the reply, without a second request. The observation covers the lots named and no others.

Material obtained directly returned 99.2%; a vial of nominally the same compound obtained through a reseller returned 99.2%. The Medutest report is retained and corresponds to the figures published by the supplier.

Import documentation was complete on first presentation. Everything wanted was in the first issue of the paperwork. Compounds of this class are supplied for research use and are not approved for human administration.

The certificate names the storage condition the stability statement was written against. The certificate labels the method as stability-indicating explicitly.

Submitted material from lot QYB-26-585 to Janoshik; the reported figure was 97.8% against a stated 97.5%. The technical reply came back inside four hours on a working day.

Labels were machine-printed, with the lot and the date readable without effort. Tracking was available end to end, and the scans matched the consignment’s progress. The observation covers the lots named and no others.

No rounding occurred between the certificate figure and the one quoted on the invoice. The certificate attributes the water result to Karl Fischer titration. The point of this submission is the paperwork, not the percentage.

A custom-synthesis enquiry produced a quotation with a stated timeline; delivery preceded that date by 2 days. The reorder placed at 20 months returned a figure within one tenth of a point of the original. The record is offered for comparison rather than as a recommendation.

Packing on the consignment examined comprised a tamper strip that had to be cut rather than peeled.

Every unit received bore the same lot string. That the method separates degradation products is stated on the document.

A repeat order of the same line placed at 6 months returned 99.3%, against 99.3% on the original.

Purity is reported by reverse-phase HPLC, and the detection wavelength is printed with it.

Duplicate determinations commissioned from separate services converged on the same purity figure to one decimal place. No listed line proved unavailable at the point of ordering.

Dispatch took place on the day quoted, and the tracking record was issued before the parcel left the facility rather than after. A release date sits beside the signature on the certificate. Contributors are asked to verify material independently regardless of submissions recorded here.

The certificate supplied with this order carried an assigned retention time for the main peak.

Dispatch was quoted at 6 days from stock held in the United States; the consignment arrived on day 6. The document identifies the method as stability-indicating. The substance here is what the documents carry rather than what one of them says.

The related-substances table names each impurity separately. The record is offered for comparison rather than as a recommendation.

The quotation covered an unusual sequence, and independent examination of what arrived agreed with the specification quoted. Tracking events corresponded to the parcel’s movements at each stage. Readers are reminded that this article publishes no score.

Every label examined was machine-printed and applied straight, with the lot and date readable at arm’s length. The certificate's stability line is qualified by a stated storage temperature rather than left open. Further submissions covering later lots would be useful.

Material from two separate lots of LL-37 5 mg was compared; the reported purities differed by one tenth of a percentage point. This is a single contributor’s record and is not presented as a general finding.

Gradient and column chemistry are both on the document, so the separation can be reproduced. Nothing in this submission constitutes medical advice.

A retention time for the main peak is printed alongside the purity figure. The certificate is dated at release and signed. The record is offered for comparison rather than as a recommendation.

Across 5 lots examined by this contributor the reported purity band is under one percentage point wide. A technical question was answered the same working day, within four hours. This contributor has placed subsequent orders with the same supplier.

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.^[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.^[3][6]

Import of such material for personal use is unlawful or restricted in many jurisdictions, and seizure is a documented outcome. PeptidePedia describes the legal position and does not advise on it.^[3]

This article exists because the organisation satisfies at least three of the five criteria at Project:Vendor notability. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.^[1][2][5]

What is not available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.^[2]

Two frameworks are named in this article only to say what has not been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,^[8] and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.^[7] Neither assessment is available here for this organisation or for any other covered on this wiki.

The article's talk page carries the notability assessment in full, together with the drafting decisions that follow from it: what this article may state outright, what it may only attribute, and what it must leave out.

• ChinaPeptides Co., Ltd. (QYAOBIO) — official site (qyaobiopeptides.com) — the organisation's own catalogue, stock listing and ordering pages. Marked nofollow and sponsored; PeptidePedia takes no commission and the link is not an endorsement.
• Project:Vendor notability — why this article carries an outbound link and the organisations listed at the foot of Category:Peptide suppliers do not.

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only
• Peptide supply chain
• Blind sampling

• Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
• Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.